CAS: 355025-24-0; 3-((4-(4-(((1-(2-Chlorophenyl)Ethoxy)Carbonyl)Amino)-3-Methylisoxazol-5-yl)Benzyl)Thio)Propanoic Acid

上下游产品

methyl 3-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)-prop-2-ynoate methyl 5-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)-3-methylisoxazole-4-carboxylate methyl 5-(4-(hydroxymethyl)phenyl)-3-methylisoxazole-4-carboxylate methyl 5-(4-(chloromethyl)phenyl)-3-methylisoxazole-4-carboxylate

📜1-(2-氯苯基)乙醇置于lithium Hydroxide Monohydrate,叠氮磷酸二苯酯,水,四丁基碘化铵,三乙胺体系中,用 四氢呋喃,二氯甲烷,甲苯 作为反应溶剂,化学反应 6.5H,反应生成 Ki 16425; 3-[[[4-[4-[[[1-(2-氯苯基)乙氧基]羰基]氨基]-3-甲基-5-异恶唑基]苯基]甲基]硫基]丙酸
参考文献:光学活性ki16425的合成及生物学评价
标题:光学活性ki16425的合成及生物学评价
摘要:实现了具有选择性lpa拮抗活性的ki16425的两个对映异构体的对映体选择性合成.异恶唑核心是通过将氧化腈与炔烃进行1,3-偶极环加成并与旋光性α-苯乙醇链段缩合而构建的,旋光性α-苯乙醇链段是通过对映体选择性还原芳基甲基酮而制得的.ki16425的两个对映异构体的生物学评估表明(R)-异构体对lpa 1和lpa 3受体具有更高的拮抗活性.
DOI:10.1016/j.Bmcl.2012.05.012

专利信息

专利号:WO-2025183657-A1
优先权日:2024-02-28
标题:Dual drug-containing ph-sensitive polymeric nanoconjugate and synthesis method thereof
发明人：GÃœNEL NUR SELVI; ÖZEL BUKET; ÅžANLIER ÅžENAY
权利人:EGE UENIVERSITESI IDARI VE MALI ISLERDAIRE BSK
摘要:The invention relates to a dual drug loaded, targeted polymer drug nanoconjugate affecting multiple signaling pathways for use as a drug delivery system in the treatment of ovarian cancer. Said nanoconjugate comprises Cabozantinib (CBZ) as a VEGFR (Vascular endothelial growth factor receptor) inhibitor and Ki16425 as a LPAR (Lysophosphatidic acid receptor) 1,2,3 inhibitor. In the nanoconjugate of the invention, synergistic effect is obtained with dual drug use.